Apimeds Pharmaceuticals US, Inc.(APUS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
APUS Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Apimeds Pharmaceuticals US, Inc. (APUS), a Healthcare sector company. APUS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Apimeds Pharmaceuticals US, Inc. reports net income of $-35.1M, free cash flow of $-2.1M. Top institutional holders of APUS by reported 13-F value include Hemenway Co, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. APUS trades on the NYSE exchange and files with the SEC under CIK 1894525. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate APUS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Apimeds Pharmaceuticals US, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-35.1M
Free Cash Flow
Q1 2026
$-2.1M
ROIC
Q1 2026
-9.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-331.7% YoYOperating Income
-834.2% YoYEPS (Diluted)
-205.6% YoYTotal Assets
+1257338.4% YoYOp. Cash Flow
-1116.8% YoY| Metric | FY 2025 | FY 2024 | FY 2022 |
|---|---|---|---|
| Net Income | $-6.0M -331.7% | $-1.4M | — |
| Operating Income | $-11.9M -834.2% | $-1.3M | — |
| EPS (Diluted) | $-0.55 -205.6% | $-0.18 | — |
| Total Assets | $164.2M +1257338.4% | $13.1K | — |
| Operating Cash Flow | $-8.9M -1116.8% | $-733.5K | — |
Get alerted when APUS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Apimeds Pharmaceuticals US, Inc. including:
Top Institutional Holders of APUS
Hemenway Trust Co LLC
$490.3K274,000 shVANGUARD CAPITAL MANAGEMENT LLC
$171.6K95,929 shGEODE CAPITAL MANAGEMENT, LLC
$71.7K40,051 shVANGUARD FIDUCIARY TRUST CO
$43.0K24,039 shTWO SIGMA SECURITIES, LLC
$18.9K10,550 shUBS Group AG
$7.5K4,187 sh
| Fund | Value | Shares |
|---|---|---|
| Hemenway Trust Co LLC | $490.3K | 274,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $171.6K | 95,929 |
| GEODE CAPITAL MANAGEMENT, LLC | $71.7K | 40,051 |
| VANGUARD FIDUCIARY TRUST CO | $43.0K | 24,039 |
| TWO SIGMA SECURITIES, LLC | $18.9K | 10,550 |
| UBS Group AG | $7.5K | 4,187 |
More Healthcare Companies
View all Healthcare →Put APUS on your watchlist
Track score changes the day Apimeds Pharmaceuticals US, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is APUS a good stock to buy?
13F Pro's AI-powered analysis of Apimeds Pharmaceuticals US, Inc. (APUS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for APUS are available on the APUS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own APUS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling APUS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Apimeds Pharmaceuticals US, Inc.'s investment landscape.